Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helena M A Feenstra

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Acta Ophthalmologica|February 12, 2026
Risk factors for the development of subretinal fluid in the fellow eyes of patients with chronic central serous chorioretinopathyHelena M A Feenstra, Tahir Cakar, Joost Brinks, et al.
Acta Ophthalmologica|September 30, 2022
Comparative efficacy of treatments for chronic central serous chorioretinopathy: A systematic review with network meta-analysesElon H C van Dijk, Helena M A Feenstra, Jakob Bjerager, et al.
Retina (Philadelphia, Pa.)|June 12, 2023
SINGLE-SESSION BILATERAL REDUCED-SETTINGS PHOTODYNAMIC THERAPY FOR BILATERAL CHRONIC CENTRAL SEROUS CHORIORETINOPATHYLaurenz J B Pauleikhoff, Roselie M H Diederen, Helena M A Feenstra, et al.
Retina (Philadelphia, Pa.)|October 26, 2023
BASELINE SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHIC RETINAL LAYER FEATURES IDENTIFIED BY ARTIFICIAL INTELLIGENCE PREDICT THE COURSE OF CENTRAL SEROUS CHORIORETINOPATHYLorenzo Ferro Desideri, Rodrigo Anguita, Lieselotte E Berger, et al.
International Journal of Retina and Vitreous|June 1, 2024
Analysis of optical coherence tomography biomarker probability detection in central serous chorioretinopathy by using an artificial intelligence-based biomarker detectorLorenzo Ferro Desideri, Rodrigo Anguita, Lieselotte E Berger, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|October 6, 2022
Long-term follow-up of chronic central serous chorioretinopathy patients after primary treatment of oral eplerenone or half-dose photodynamic therapy and crossover treatment: SPECTRA trial report No. 3Helena M A Feenstra, Elon H C van Dijk, Thomas J van Rijssen, et al.
Ophthalmology. Retina|April 26, 2022
Crossover to Half-Dose Photodynamic Therapy or Eplerenone in Chronic Central Serous Chorioretinopathy PatientsHelena M A Feenstra, Elon H C van Dijk, Thomas J van Rijssen, et al.
European Heart Journal|January 21, 2016
Genotype impacts survival in Marfan syndromeRomy Franken, Maarten Groenink, Vivian de Waard, et al.
Acta Ophthalmologica|February 12, 2026
Long-term follow-up of chronic central serous chorioretinopathy patients receiving oral eplerenone and half-dose photodynamic therapy in the SPECTRA trial: SPECTRA trial report No. 4Helena M A Feenstra, Issam El Mansori, Thomas J van Rijssen, et al.
American Journal of Ophthalmology|July 2, 2021
Half-Dose Photodynamic Therapy Versus Eplerenone in Chronic Central Serous Chorioretinopathy (SPECTRA): A Randomized Controlled TrialThomas J van Rijssen, Elon H C van Dijk, Roula Tsonaka, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Acta Ophthalmologica|February 12, 2026
Risk factors for the development of subretinal fluid in the fellow eyes of patients with chronic central serous chorioretinopathyHelena M A Feenstra, Tahir Cakar, Joost Brinks, et al.
Acta Ophthalmologica|September 30, 2022
Comparative efficacy of treatments for chronic central serous chorioretinopathy: A systematic review with network meta-analysesElon H C van Dijk, Helena M A Feenstra, Jakob Bjerager, et al.
Retina (Philadelphia, Pa.)|June 12, 2023
SINGLE-SESSION BILATERAL REDUCED-SETTINGS PHOTODYNAMIC THERAPY FOR BILATERAL CHRONIC CENTRAL SEROUS CHORIORETINOPATHYLaurenz J B Pauleikhoff, Roselie M H Diederen, Helena M A Feenstra, et al.
Retina (Philadelphia, Pa.)|October 26, 2023
BASELINE SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHIC RETINAL LAYER FEATURES IDENTIFIED BY ARTIFICIAL INTELLIGENCE PREDICT THE COURSE OF CENTRAL SEROUS CHORIORETINOPATHYLorenzo Ferro Desideri, Rodrigo Anguita, Lieselotte E Berger, et al.
International Journal of Retina and Vitreous|June 1, 2024
Analysis of optical coherence tomography biomarker probability detection in central serous chorioretinopathy by using an artificial intelligence-based biomarker detectorLorenzo Ferro Desideri, Rodrigo Anguita, Lieselotte E Berger, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|October 6, 2022
Long-term follow-up of chronic central serous chorioretinopathy patients after primary treatment of oral eplerenone or half-dose photodynamic therapy and crossover treatment: SPECTRA trial report No. 3Helena M A Feenstra, Elon H C van Dijk, Thomas J van Rijssen, et al.
Ophthalmology. Retina|April 26, 2022
Crossover to Half-Dose Photodynamic Therapy or Eplerenone in Chronic Central Serous Chorioretinopathy PatientsHelena M A Feenstra, Elon H C van Dijk, Thomas J van Rijssen, et al.
European Heart Journal|January 21, 2016
Genotype impacts survival in Marfan syndromeRomy Franken, Maarten Groenink, Vivian de Waard, et al.
Acta Ophthalmologica|February 12, 2026
Long-term follow-up of chronic central serous chorioretinopathy patients receiving oral eplerenone and half-dose photodynamic therapy in the SPECTRA trial: SPECTRA trial report No. 4Helena M A Feenstra, Issam El Mansori, Thomas J van Rijssen, et al.
American Journal of Ophthalmology|July 2, 2021
Half-Dose Photodynamic Therapy Versus Eplerenone in Chronic Central Serous Chorioretinopathy (SPECTRA): A Randomized Controlled TrialThomas J van Rijssen, Elon H C van Dijk, Roula Tsonaka, et al.
Pageof 2